Clinical Trial Update: Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating 80 mg osimertinib in patients with non-small cell lung cancer has completed, reporting on efficacy and safety. The study was sponsore…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED